How have FPHAF shares performed in 2024?

Faron Pharmaceuticals Oy's stock was trading at $3.30 at the start of the year. Since then, FPHAF shares have increased by 0.0% and is now trading at $3.30. View the best growth stocks for 2024 here .

How do I buy shares of Faron Pharmaceuticals Oy?

Shares of FPHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTC:FPHAF

Faron Pharmaceuticals Oy (FPHAF) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Buy FPHAF with Qtrade

Free FPHAF Stock Alerts

$3.30

0.00 (0.00%)

(As of 05/12/2023)

Compare

Today's Range: $3.30
▼
$3.30
50-Day Range: $3.30
▼
$3.30
52-Week Range: $3.10
▼
$6.00

Volume: N/A
Average Volume: 3,650 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis

Get Faron Pharmaceuticals Oy alerts:

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company's lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. It also develops Haematokine, an investigational AOC3 inhibitor that is used for regenerative medicines in hematological malignancies, as well as chemotherapy induced suppression of the bone marrow. In addition, the company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.

FPHAF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

FPHAF Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive FPHAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Faron Pharmaceuticals Oy and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTC
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: OTC:FPHAF
CUSIP: N/A
CIK: N/A
Web: www.faron.com
Phone: 358.2.469.5151
Fax: N/A
Employees: 40
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Dr. Juho Markku Jalkanen M.D. (Age 45)
MSc, Ph.D., Chief Operating Officer
Comp: $482.83k
Dr. Markku Tapani Jalkanen Ph.D. (Age 69)
Founder, CEO & Exec. Director
Mr. James M. O'Brien CPA
M.B.A., Chief Financial Officer
Dr. Maija Hollmen Ph.D.
Chief Scientific Officer
Mr. Vesa Karvonen L.L.M. (Age 51)
Gen. Counsel
Ms. Jennifer Smith-Parker
Head of Communications
Juuso Vakkuri M.A.
M.B.A., M.Sc., Chief HR Officer
Dr. Juhana Heinonen
Chief Commercial Officer
Dr. Marie-Louise Fjallskog M.D. (Age 59)
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

FPHAF Stock Analysis - Frequently Asked Questions

How have FPHAF shares performed in 2024?: Faron Pharmaceuticals Oy's stock was trading at $3.30 at the start of the year. Since then, FPHAF shares have increased by 0.0% and is now trading at $3.30.
View the best growth stocks for 2024 here.
How do I buy shares of Faron Pharmaceuticals Oy?: Shares of FPHAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTC:FPHAF) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial